An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis

Journal of Immunology

Volumn 177, Issue 7, 2006, Pages 4917-4926

  Toichi, Eiko ^a,b   Torres, Gisela ^a   McCormick, Thomas S ^a   Chang, Timothy ^a   Mascelli, Mary Ann ^c   Kauffman, Catharine L ^d   Aria, Nancy ^d   Gottlieb, Alice B ^e   Everitt, Daniel E ^c   Frederick, Bart ^c   Pendley, Charles E ^c   Cooper, Kevin D ^a,f  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CENTOCOR INC   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 12P40 ANTIBODY; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DOWN REGULATION; EFFECTOR CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; SKIN BIOPSY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 33749151636     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.7.4917     Document Type: Article

References (75)

1. Valdimarsson, H., B. S. Baker, I. Jonsdottir, and L. Fry. 1986. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol. Today 7: 256-259.
2. + perivascular dendritic cells. J. Invest. Dermatol. 96: 333-340.
3. Wrone-Smith, T., and B. J. Nickoloff. 1996. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98: 1878-1887.
4. Brooks, D. B. 1986. Clearance of psoriasis with low dose cyclosporine. Br. Med. J. 293: 1098-1099.
5. Gottlieb, S. L., P. Gilleaudeau, R. Johnson, L. Estes, T. G. Woodworth, A. B. Gottlieb, and J. G. Krueger. 1995. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1: 442-447.
6. Abrams, J. R., M. G. Lebwohl, C. A. Guzzo, B. V. Jegasothy, M. T. Goldfarb, B. S. Goffe, A. Menter, N. J. Lowe, G. Krueger, M. J. Brown, et al. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103: 1243-1252.
7. Ellis, C. N., and G. G. Krueger. 2001. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345: 248-255.
8. Boyman, O., H. P. Hefti, C. Conrad, B. J. Nickoloff, M. Suter, and F. O. Nestle. 2004. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J. Exp. Med. 199: 731-736.
9. Baadsgaard, O., A. K. Gupta, R. S. Taylor, C. N. Ellis, J. J. Voorhees, and K. D. Cooper. 1989. Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells. J. Invest. Dermatol. 92: 190-195.
10. Nestle, F. O., L. A. Turka, and B. J. Nickoloff. 1994. Characterization of dermal dendritic cells in psoriasis: autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Invest. 94: 202-209.
11. Cooper, K. D., O. Baadsgaard, C. N. Ellis, E. Duell, and J. J. Voorhees. 1990. Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis. J. Invest. Dermatol. 94: 649-656.
12. Ho, V. C., C. E. M. Griffiths, C. N. Ellis, A. K. Gupta, C. C. McCuaig, B. J. Nickoloff, K. D. Cooper, T. A. Hamilton, and J. J. Voorhees. 1990. Intralesional cyclosporine in the treatment of psoriasis: a clinical, immunologic, and pharmacokinetic study. J. Am. Acad. Dermatol. 22: 94-100.
13. Bata-Csorgo, Z., C. Hammerberg, J. J. Voorhees, and K. D. Cooper. 1995. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture: cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J. Clin. Invest. 95: 317-327.
14. Barker, J. N., G. D. Karabin, T. J. Stoof, V. J. Sarma, V. M. Dixit, and B. J. Nickoloff. 1991. Detection of interferon-γ mRNA in psoriatic epidermis by polymerase chain reaction. J. Dermatol. Sci. 2: 106-111.
15. + subsets. J. Invest. Dermatol. 111: 1072-1078.
16. Schlaak, J. F., M. Buslau, W. Jochum, E. Hermann, M. Girndt, H. Gallati, K.-H. Buschenfelde, and B. Fleischer. 1994. T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Invest. Dermatol. 102: 145-149.
17. Austin, L. M., M. Ozawa, T. Kikuchi, I. B. Walters, and J. G. Krueger. 1999. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113: 752-759.
18. Uyemura, K., M. Yamamura, D. F. Fivenson, R. L. Modlin, and B. J. Nickoloff. 1993. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J. Invest. Dermatol. 101: 701-705.
19. Billiau, A., H. Heremans, F. Vandekerckhove, R. Dijkmans, H. Sobis, E. Meulepas, and H. Carton. 1988. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-γ. J. Immunol. 140: 1506-1510.
20. Lublin, F. D., R. L. Knobler, B. Kalman, M. Goldhaber, J. Marini, M. Perrault, C. D'Imperio, J. Joseph, S. S. Alkan, and R. Korngold. 1993. Monoclonal anti-γ-interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity 16: 267-274.
21. Mease, P. J., B. S. Goffe, J. Metz, A. VanderStoep, B. Finck, and D. J. Burge. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356: 385-390.
22. Chaudhari, U., P. Romano, L. D. Mulcahy, L. T. Dooley, D. G. Baker, and A. B. Gottlieb. 2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357: 1842-1847.
23. Gately, M. K., L. M. Renzetti, J. Magram, A. S. Stern, L. Adorini, U. Gubler, and D. H. Presky. 1998. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16: 495-521.
24. Trinchieri, G. 1995. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13: 251-276.
25. Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70: 83-243.
26. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
27. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549.
28. Manetti, R., P. Parronchi, M. G. Giudizi, M.-P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12) induces T helper Type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177: 1199-1204.
29. Kang, K., M. Kubin, K. D. Cooper, S. R. Lessin, G. Trinchieri, and A. H. Rook. 1996. IL-12 synthesis by human Langerhans Cells. J. Immunol. 156: 1402-1407.
30. Yawalkar, N., S. Karlen, R. Hunger, C. U. Brand, and L. R. Braathen. 1998. Expression of interleukin-12 is increased in psoriatic skin. J. Invest. Dermatol. 111: 1053-1057.
31. Oppmann, B., R. Lesley, B. Blom, J. C. Timans, Y. Xu, B. Hunte, F. Vega, N. Yu, J. Wang, K. Singh, et al. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.
32. Wiekowski, M. T., M. W. Leach, E. W. Evans, L. Sullivan, S. C. Chen, G. Vassileva, J. F. Bazan, D. M. Gorman, R. A. Kastelein, S. Narula, and S. A. Lira. 2001. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J. Immunol. 166: 7563-7570.
33. Kopp, T., P. Lenz, C. Bello-Fernandez, R. A. Kastelein, T. S. Kupper, and G. Stingl. 2003. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J. Immunol. 170: 5438-5444.
34. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
35. Li, J., B. Gran, G. X. Zhang, E. S. Ventura, I. Siglienti, A. Rostami, and M. Kamoun. 2003. Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia. J. Neurol. Sci. 215: 95-103.
36. Lee, E., W. L. Trepicchio, J. L. Oestreicher, D. Pittman, F. Wang, F. Chamian, M. Dhodapkar, and J. G. Krueger. 2004. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199: 125-130.
37. Leonard, J. P., K. E. Waldburger, and S. J. Goldman. 1995. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181: 381-386.
38. Simpson, S. J., S. Shah, M. Comiskey, Y. P. de Jong, B. Wang, E. Mizoguchi, A. K. Bhan, and C. Terhorst. 1998. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon-γ expression by T cells. J. Exp. Med. 187: 1225-1234.
39. Davidson, N. J., S. A. Hudak, R. E. Lesley, S. Menon, M. W. Leach, and D. M. Rennick. 1998. IL-12, but not IFN-γ, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J. Immunol. 161: 3143-3149.
40. Neurath, M. F., I. Fuss, B. L. Kelsall, E. Stuber, and W. Strober. 1995. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182: 1281-1290.
41. Malfait, A. M., D. M. Butler, D. H. Presky, R. N. Maini, F. M. Brennan, and M. Feldmann. 1998. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin. Exp. Immunol. 111: 377-383.
42. Matthys, P., K. Vermeire, T. Mitera, H. Heremans, S. Huang, and A. Billiau. 1998. Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-γ receptor-deficient mice. Eur. J. Immunol. 28: 2143-2151.
43. Yokoi, H., K. Kato, T. Kezuka, J. Sakai, M. Usui, H. Yagita, and K. Okumura. 1997. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12. Eur. J. Immunol. 27: 641-646.
44. Hong, K., A. Chu, B. R. Ludviksson, E. L. Berg, and R. O. Ehrhardt. 1999. IL-12, independently of IFN-γ, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 162: 7480-7491.
45. Kauffman, C. L., N. Arai, E. Toichi, T. S. McCormick, K. D. Cooper, A. B. Gottlieb, D. E. Everitt, B. Frederick, Y. Zhu, M. A. Graham, et al. 2004. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123: 1037-1044.
46. Fredriksson, T., and U. Pettersson. 1978. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157: 238-244.
47. Trepicchio, W. L., M. Ozawa, I. B. Walters, T. Kikuchi, P. Gilleaudeau, J. L. Bliss, U. Schwertschlag, A. J. Dorner, and J. G. Krueger. 1999. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest. 104: 1527-1537.
48. Ghoreschi, K., P. Thomas, S. Breit, M. Dugas, R. Mailhammer, W. van Eden, R. van der Zee, T. Biedermann, J. Prinz, M. Mack, et al. 2003. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9: 40-46.
49. Chamian, F., M. A. Lowes, S. L. Lin, E. Lee, T. Kikuchi, P. Gilleaudeau, M. Sullivan-Whalen, I. Cardinale, A. Khatcherian, I. Novitskaya, et al. 2005. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl. Acad. Sci. USA 102: 2075-2080.
50. Raychaudhuri, S. P., W. Y. Jiang, E. M. Farber, T. J. Schall, M. R. Ruff, and C. B. Pert. 1999. Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta. Derm. Venereol. 79: 9-11.
51. Gillitzer, R., R. Berger, V. Mielke, C. Muller, K. Wolff, and O. Stingl. 1991. Upper keratinocytes of psoriatic skin lesions express high levels of NAP-I/IL-8 mRNA in situ. J. Invest. Dermatol. 97: 73-79.
52. Giustizieri, M. L., F. Mascia, A. Frezzolini, O. De Pita, L. M. Chinni, A. Giannetti, G. Girolomoni, and S. Pastore. 2001. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J. Allergy Clin. Immunol. 107: 871-877.
53. Lowes, M. A., F. Chamian, M. V. Abello, J. Fuentes-Duculan, S. L. Lin, R. Nussbaum, I. Novitskaya, H. Carbonaro, I. Cardinale, T. Kikuchi, et al. 2005. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. USA 102: 19057-19062.
54. Ma, X. J., J. M. Chow, G. Gri, G. Carra, F. Gerosa, S. E. Wolf, R. Dzialo, and G. Trincheri. 1996. The interleukin 12 p40 gene promoter is primed by interferon-γ in monocytic cells. J. Exp. Med. 183: 147.
55. high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 174: 164-173.
56. Aggarwal, S., N. Ghilardi, M. H. Xie, F. J. de Sauvage, and A. L. Gurney. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278: 1910-1914.
57. Nestle, F. O., C. Conrad, A. Tun-Kyi, B. Homey, M. Gombert, O. Boyman, G. Burg, Y. J. Liu, and M. Gilliet. 2005. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J. Exp. Med. 202: 135-143.
58. Blauvelt, A. 2004. In this issue-full court press on psoriasis. J. Invest. Dermatol. 123: vii-viii.
59. Nestle, F. O., and C. Conrad. 2004. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J. Invest. Dermatol. 123: xiv-xv.
60. Asadullah, K., W. Sterry, K. Stephanek, D. Jasulaitis, M. Leupold, H. Audring, H. D. Volk, and W. D. Docke. 1998. IL-10 is a key cytokine in psoriasis: proof of principle by IL-10 therapy: a new therapeutic approach. J. Clin. Invest. 101: 783-794.
61. Friedrich, M., W. D. Docke, A. Klein, S. Philipp, H. D. Volk, W. Sterry, and K. Asadullah. 2002. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J. Invest. Dermatol. 118: 672-677.
62. Kimball, A. B., T. Kawamura, K. Tejura, C. Boss, A. R. Hancox, J. C. Vogel, S. M. Steinberg, M. L. Turner, and A. Blauvelt. 2002. Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch. Dermatol. 138: 1341-1346.
63. Olaniran, A. K., B. S. Baker, D. G. Paige, J. J. Garioch, A. V. Powles, and L. Fry. 1996. Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch. Dermatol. Res. 288: 421-425.
64. + macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represent the major secretory source of epidermal IL-10 protein. J. Immunol. 153: 5256-5264.
65. D'Andrea, A., M. Aste-Amezaga, N. M. Valiante, X. Ma, M. Kubin, and G. Trinchieri. 1993. Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178: 1041-1048.
66. Aste-Amezaga, M., X. Ma, A. Sartori, and G. Trinchieri. 1998. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J. Immunol. 160: 5936-5944.
67. Nakanishi, K., T. Yoshimoto, H. Tsutsui, and H. Okamura. 2001. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 19: 423-474.
68. Ohta, Y., Y. Hamada, and K. Katsuoka. 2001. Expression of IL-18 in psoriasis. Arch. Dermatol. Res. 293: 334-342.
69. Li, J., G. W. Ireland, P. M. Farthing, and M. H. Thornhill. 1996. Epidermal and oral keratinocytes are induced to produce RANTES and IL-8 by cytokine stimulation. J. Invest. Dermatol. 106: 661-666.
70. Boorsma, D. M., J. Flier, S. Sampat, C. Ottevanger, P. de Haan, L. Hooft, R. Willemze, C. P. Tensen, and T. J. Stoof. 1998. Chemokine IP-10 expression in cultured human keratinocytes. Arch. Dermatol. Res. 290: 335-341.
71. Krueger, G., and K. Callis. 2004. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch. Dermatol. 140: 218-225.
72. Kaluza, W., E. Reuss, S. Grossmann, R. Hug, R. E. Schopf, P. R. Galle, E. Maerker-Hermann, and T. Hoehler. 2000. Different transcriptional activity and in vitro TNF-α production in psoriasis patients carrying the TNF-α 238A promoter polymorphism. J. Invest. Dermatol. 114: 1180-1183.
73. Johansen, C., A. T. Funding, K. Otkjaer, K. Kragballe, U. B. Jensen, M. Madsen, L. Binderup, T. Skak-Nielsen, M. S. Fjording, and L. Iversen. 2006. Protein expression of TNF-α in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J. Immunol. 176: 1431-1438.
74. Pradines-Figueres, A., and C. R. Raetz. 1992. Processing and secretion of tumor necrosis factor α in endotoxin-treated Mono Mac 6 cells are dependent on phorbol myristate acetate. J. Biol. Chem. 267: 23261-23268.
75. Mannon, P. J., I. J. Fuss, L. Mayer, C. O. Elson, W. J. Sandborn, D. Present, B. Dolin, N. Goodman, C. Groden, R. L. Hornung, et al. 2004. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351: 2069-2079.